Basilea Pharmaceutica AG/ CH0011432447 /
| 2024-11-13 5:19:30 PM | Chg. -0.30 | Volume | Bid5:20:00 PM | Ask5:20:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 40.80CHF | -0.73% | 3,481 Turnover: 142,259.60 |
-Bid Size: - | -Ask Size: - | 537.09 mill.CHF | - | 47.13 |
Assets
| 2016 US GAAP in mill. CHF |
2017 US GAAP in mill. CHF |
2018 US GAAP in mill. CHF |
2019 US GAAP in mill. CHF |
2020 US GAAP in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 8.9000 | 7.8000 | 6.4000 | 5.2000 | 2.6000 | ||||||
| Intangible Assets | .2000 | .3000 | .4000 | .4000 | .7000 | ||||||
| Long-Term Investments | 50 | 50 | 0.0000 | 30 | 0.0000 | ||||||
| Fixed Assets | 59.3000 | 58.2000 | 7 | 36.6000 | 6.3000 | ||||||
| Inventories | 14.9000 | 15.3000 | 14.4000 | 18.6000 | 21.2000 | ||||||
| Accounts Receivable | 2.5000 | 5 | 3.8000 | 6.2000 | 8.7000 | ||||||
| Cash and Cash Equivalents | 239 | 200.7000 | 173 | 109 | 60.7000 | ||||||
| Current Assets | 268.5000 | 293 | 274.7000 | 184.9000 | 223.5000 | ||||||
| Total Assets | 327.8000 | 351.2000 | 281.8000 | 221.5000 | 229.8000 | ||||||
Liabilities
| 2016 US GAAP in mill. CHF |
2017 US GAAP in mill. CHF |
2018 US GAAP in mill. CHF |
2019 US GAAP in mill. CHF |
2020 US GAAP in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 1.9000 | 4.4000 | 6.4000 | 6.8000 | 13.2000 | ||||||
| Long-term debt | 195.5000 | 196.2000 | 197 | 197.7000 | 239.7000 | ||||||
| Liabilities to Banks | 195.5000 | 196.2000 | 197 | 197.7000 | 239.7000 | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 362.8000 | 392.6000 | 348.4000 | 314.4000 | 331.8000 | ||||||
| Share Capital | - | - | - | - | - | ||||||
| Total Equity | -35 | -41.4000 | -66.7000 | -93 | -102 | ||||||
| Minority Interests | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Total liabilities equity | 327.8000 | 351.2000 | 281.8000 | 221.5000 | 229.8000 | ||||||
Income Statement
| 2016 US GAAP in mill. CHF |
2017 US GAAP in mill. CHF |
2018 US GAAP in mill. CHF |
2019 US GAAP in mill. CHF |
2020 US GAAP in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 66 | 101.5000 | 132.6000 | 134.4000 | 127.6000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -43.9000 | -14.1000 | -24.1000 | -17.2000 | -8.2000 | ||||||
| Interest Income | - | - | - | - | - | ||||||
| Income Before Taxes | -51 | -19 | -31.2000 | -22.4000 | -14.7000 | ||||||
| Income Taxes | -.3000 | -.4000 | -.2000 | 0.0000 | 0.0000 | ||||||
| Minority Interests Profit | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Net Income | -51.3000 | -19.4000 | -31.4000 | -22.4000 | -14.7000 | ||||||
Per Share
Cash Flow
| 2016 US GAAP in mill. CHF |
2017 US GAAP in mill. CHF |
2018 US GAAP in mill. CHF |
2019 US GAAP in mill. CHF |
2020 US GAAP in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -75 | 19 | -79.2000 | -63.8000 | -54.1000 | ||||||
| Cash Flow from Investing Activities | 1.2000 | -60.9000 | 59.4000 | -.4000 | -35 | ||||||
| Cash Flow from Financing | .4000 | 2.6000 | -6 | 1.3000 | 45.1000 | ||||||
| Decrease / Increase in Cash | -74 | -38.3000 | -26.8000 | -62.9000 | -44.8000 | ||||||
| Employees | 240 | 230 | 227 | 225 | 150 | ||||||
